Skip Navigation

Radiation & Cancer Biology
Division Overview

Yi Sun, MD, PhD: Director
of Radiation & Cancer Biology

The Radiation and Cancer Biology Division in the Department of Radiation Oncology of the University of Michigan was established in 1995. Overall goals of this division are to understand the mechanism of cellular response to radiation and to identify and target the molecules and signaling pathways that are responsible to radioresistance in human cancer. The ultimate goal is to improve current radiation therapy alone and in combination with chemotherapy for the treatment of cancer patients.

The projects undertaken by Faculty range from early target identification, to mechanistic study of signaling molecules, and to application of laboratory knowledge in clinic radiotherapy. Many state-of-art technologies are being used, including nanotechnology, transgenic and knockout mice, high throughput screening of siRNA library, and functional imaging.

Faculty Members

F_Feng F_Feng Lawrence Livant Ljungman Morgan Nyati S_Nyati
Ahsan
Feng
Lawrence
Livant
Ljungman
Morgan
M. Nyati
S. Nyati
Ray Sun Sun          
D. Ray
P. Ray
Sun
 
 
 
 
 

Research Projects

Aarif Ahsan, PhD:

Felix Feng, MD: Identification of biomarkers (e.g. ETS) of radiation response in prostate cancer, and development of targeted radiosensitizers based on these biomarkers.

Ted Lawrence, MD, PhD: Combining chemoradiation with molecularly targeted therapy; Preclinical studies in the treatment of hepatocellular cancer.

Donna Livant, PhD: α5b1 integrin fibronectin receptor in invasion/metastasis, angiogenesis and tumor growth, and development of signaling inhibitors as efficacious therapeutic agents.

Mats Ljungman, PhD: Understanding the cellular responses to DNA-damaging agents and stress-induced gene expression with identification of molecular targets for novel cancer treatments.

Meredith Morgan, PhD: Combination of novel molecularly targeted agents with chemoradiation to improve therapy for pancreatic carcinoma.

Mukesh Nyati, PhD: Understanding the key signaling events predictive of response to EGFR inhibition and investigating optimum schedules for combination of molecularly targeted drugs with chemo- and radiotherapy.

Shyam Nyati, PhD:

Dipankar Ray, PhD: Understanding the molecular alterations during radiation-induced lung toxicity and identifying new therapeutic targets for thoracic cancers.

Paramita Ray, PhD:

Yi Sun, MD, PhD: SAG/RBX2/ROC2 E3 ubiquitin ligase and p53 signal pathways in human cancer; Discovery of novel radiosensitizing targets and radiosensitizers.


Back to top